Loading...
Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. The last earnings update was 8 days ago. More info.
7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
---|---|---|---|---|---|---|
Canopy Growth (WEED) | -5.4% | 2.2% | 33.9% | 113% | 1948.6% | - |
CA Pharmaceuticals | -0.6% | 9.5% | 19.7% | -8.1% | 887.4% | -30.3% |
CA Market | 2.2% | 4.5% | 5.4% | 0.5% | 24% | 6.1% |
Is Canopy Growth undervalued based on future cash flows and its price relative to the stock market?
Data Point | Source | Value |
---|---|---|
Earnings Per Share * | Company Filings (2018-12-31) in CAD | CA$-1.79 |
TSX:WEED Share Price ** | TSX (2019-02-21) in CAD | CA$59.41 |
Canada Pharmaceuticals Industry PE Ratio | Median Figure of 15 Publicly-Listed Pharmaceuticals Companies | 21.51x |
Canada Market PE Ratio | Median Figure of 552 Publicly-Listed Companies | 14.82x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Canopy Growth.
Calculation | Outcome | |
---|---|---|
PE Ratio | = TSX:WEED Share Price ÷ EPS (both in CAD) = 59.41 ÷ -1.79 |
-33.27x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value |
---|---|---|
PE Ratio | See PE Ratio Section | -33.27x |
Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts |
96.9%per year |
Canada Pharmaceuticals Industry PEG Ratio | Median Figure of 10 Publicly-Listed Pharmaceuticals Companies | 0.9x |
Canada Market PEG Ratio | Median Figure of 257 Publicly-Listed Companies | 0.94x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value |
---|---|---|
Book Value per Share | Company Filings (2018-12-31) in CAD | CA$21.07 |
TSX:WEED Share Price * | TSX (2019-02-21) in CAD | CA$59.41 |
Canada Pharmaceuticals Industry PB Ratio | Median Figure of 120 Publicly-Listed Pharmaceuticals Companies | 3.25x |
Canada Market PB Ratio | Median Figure of 2,330 Publicly-Listed Companies | 1.55x |
Calculation | Outcome | |
---|---|---|
PB Ratio | = TSX:WEED Share Price ÷ Book Value per Share (both in CAD) = 59.41 ÷ 21.07 |
2.82x |
* Primary Listing of Canopy Growth.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Data Point | Source | Value (per year) |
---|---|---|
TSX:WEED Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts | 96.9% |
TSX:WEED Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 11 Analysts | 47.4% |
Canada Pharmaceuticals Industry Earnings Growth Rate | Market Cap Weighted Average | 85.8% |
Canada Pharmaceuticals Industry Revenue Growth Rate | Market Cap Weighted Average | 49.2% |
Canada Market Earnings Growth Rate | Market Cap Weighted Average | 18% |
Canada Market Revenue Growth Rate | Market Cap Weighted Average | 6.9% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Data Point | Source | Value |
---|---|---|
Past Financials | Company Filings (1 month ago) | See Below |
Future Estimates | Average of up to 11 Analyst Estimates (S&P Global) | See Below |
Date (Data in CAD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
---|---|---|---|---|
2023-03-31 | 2,408 | 1 | ||
2022-03-31 | 1,743 | 2 | ||
2021-03-31 | 1,343 | 189 | 7 | |
2020-03-31 | 813 | -142 | 10 | |
2019-03-31 | 242 | -415 | -427 | 11 |
Date (Data in CAD Millions) | Revenue | Cash Flow | Net Income * |
---|---|---|---|
2018-12-31 | 155 | -332 | -411 |
2018-09-30 | 94 | -257 | -477 |
2018-06-30 | 88 | -137 | -142 |
2018-03-31 | 78 | -82 | -70 |
2017-12-31 | 70 | -60 | -21 |
2017-09-30 | 58 | -41 | -19 |
2017-06-30 | 49 | -36 | -13 |
2017-03-31 | 40 | -27 | -8 |
2016-12-31 | 30 | -14 | -1 |
2016-09-30 | 24 | -16 | -7 |
2016-06-30 | 18 | -14 | -8 |
2016-03-31 | 13 | -14 | -3 |
*GAAP earnings excluding extraordinary items.
Data Point | Source | Value |
---|---|---|
Past Financials | Company Filings (1 month ago) | See Below |
Future Estimates | Average of up to 11 Analyst Estimates (S&P Global) | See Below |
All data from Canopy Growth Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
Date (Data in CAD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
---|---|---|---|---|
2023-03-31 | ||||
2022-03-31 | ||||
2021-03-31 | 0.33 | 0.35 | 0.31 | 2.00 |
2020-03-31 | -0.43 | -0.29 | -0.60 | 4.00 |
2019-03-31 | -1.65 | -0.71 | -2.36 | 4.00 |
Date (Data in CAD Millions) | EPS * |
---|---|
2018-12-31 | -1.79 |
2018-09-30 | -2.39 |
2018-06-30 | -0.76 |
2018-03-31 | -0.40 |
2017-12-31 | -0.13 |
2017-09-30 | -0.13 |
2017-06-30 | -0.09 |
2017-03-31 | -0.06 |
2016-12-31 | -0.01 |
2016-09-30 | -0.07 |
2016-06-30 | -0.09 |
2016-03-31 | -0.05 |
*GAAP earnings excluding extraordinary items.
How has Canopy Growth performed over the past 5 years?
All data from Canopy Growth Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
Date (Data in CAD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
---|---|---|---|---|
2018-12-31 | 155.10 | -411.38 | 445.62 | 8.50 |
2018-09-30 | 93.75 | -477.37 | 329.07 | 3.53 |
2018-06-30 | 87.99 | -141.58 | 180.24 | 2.08 |
2018-03-31 | 77.95 | -70.35 | 131.13 | 1.45 |
2017-12-31 | 69.80 | -20.80 | 94.76 | 0.38 |
2017-09-30 | 57.86 | -19.39 | 65.74 | 0.53 |
2017-06-30 | 48.78 | -12.63 | 50.47 | 0.54 |
2017-03-31 | 39.90 | -7.52 | 38.55 | 0.81 |
2016-12-31 | 30.28 | -0.65 | 29.47 | 1.63 |
2016-09-30 | 24.01 | -6.96 | 24.65 | 1.38 |
2016-06-30 | 17.97 | -8.46 | 20.53 | 1.09 |
2016-03-31 | 12.70 | -3.50 | 17.33 | 0.72 |
2015-12-31 | 8.41 | 0.32 | 12.83 | 0.49 |
2015-09-30 | 5.57 | 1.00 | 11.00 | 0.34 |
2015-06-30 | 3.42 | -5.30 | 9.72 | 0.19 |
2015-03-31 | 1.90 | -7.48 | 8.10 | 0.21 |
2014-12-31 | 1.15 | -8.93 | 6.99 | 0.16 |
2014-09-30 | 0.50 | -7.07 | 5.32 | 0.12 |
2013-12-31 | -0.93 | 0.93 |
*GAAP earnings excluding extraordinary items.
How is Canopy Growth's financial health and their level of debt?
All data from Canopy Growth Company Filings, last reported 1 month ago.
Date (Data in CAD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
---|---|---|---|
2018-12-31 | 7,423.68 | 791.50 | 4,933.50 |
2018-09-30 | 1,840.82 | 910.16 | 448.16 |
2018-06-30 | 1,224.46 | 620.29 | 657.90 |
2018-03-31 | 1,243.24 | 8.42 | 322.56 |
2017-12-31 | 1,019.86 | 8.79 | 237.71 |
2017-09-30 | 731.57 | 9.58 | 108.21 |
2017-06-30 | 682.86 | 9.91 | 115.49 |
2017-03-31 | 639.73 | 10.33 | 101.80 |
2016-12-31 | 251.52 | 7.17 | 92.50 |
2016-09-30 | 171.62 | 7.44 | 45.38 |
2016-06-30 | 132.38 | 4.13 | 19.53 |
2016-03-31 | 123.79 | 4.02 | 15.40 |
2015-12-31 | 132.05 | 3.97 | 19.72 |
2015-09-30 | 112.27 | 5.90 | 7.73 |
2015-06-30 | 42.92 | 1.89 | 15.17 |
2015-03-31 | 41.41 | 1.92 | 21.45 |
2014-12-31 | 21.67 | 1.88 | 5.77 |
2014-09-30 | 23.18 | 0.00 | 8.36 |
2013-12-31 | 3.83 | 0.04 | 2.09 |
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
What is Canopy Growth's current dividend yield, its reliability and sustainability?
Data Point | Source | Value |
---|---|---|
Past Annualized Dividend Yield | S&P Global Market Data | See Below |
Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
Future Dividends per Share Estimates | Average of up to 11 Analyst Estimates (S&P Global) | See Below |
North America Pharmaceuticals Industry Average Dividend Yield | Market Cap Weighted Average of 10 Stocks | 2.7% |
Canada Market Average Dividend Yield | Market Cap Weighted Average of 331 Stocks | 3.5% |
Canada Minimum Threshold Dividend Yield | 10th Percentile | 1.1% |
Canada Bottom 25% Dividend Yield | 25th Percentile | 2.1% |
Canada Top 25% Dividend Yield | 75th Percentile | 5.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
Date (Data in CA$) | Dividend per Share (annual) | Avg. No. Analysts |
---|---|---|
2023-03-31 | ||
2022-03-31 | ||
2021-03-31 | ||
2020-03-31 | ||
2019-03-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
Mr. Bruce A. Linton, BPA serves as Chief Executive Officer and Chairman at Canopy Rivers Inc. and serves its Director since April 2017 and served as Acting Chief Executive Officer. Mr. Linton is a Co-Founder of Canopy Growth Corporation (formerly Tweed Marijuana Inc) and has been its Co-Chief Executive Officer since August 28, 2014. Mr. Linton serves as the Chief Executive Officer and President for Clearford's two divisions: the Wastewater Systems Division and the Brooklin Concrete Division. He also served as the Chief Executive Officer and President at Martello Technologies, Inc. He has been Vice President of SC Stormont Inc., since January 2005. He served as Interim Chief Executive Officer of Canopy Growth Corporation (formerly Tweed Marijuana Inc). from August 2014 to February 2015. He served as the Chief Executive Officer of Clearford Industries Inc. (now known as Clearford Water Systems Inc.) from February 28, 2005 to December 31, 2012 and served as its President from February 28, 2005 to May 28, 2012. He served as Chief Executive Officer and President of Brooklin Concrete Products Limited. He served as the Chief Executive Officer of IWSSI. He served as the President of Clearford Industries from August 2009 to May 28, 2012. He was Re-Founder of Computerland.ca., and served as its General Manager from April 2002 to December 2004. He Co-founded webHancer Corp. in 1999 and served as its President and Chief Executive Officer. He has more than 10 years of senior executive experience in technology based companies, including Crosskeys Systems Corp. He has significant and recent experience with the introduction of both CrossKeys and Clearford to the Asia Pacific region. He has established regular engagement with the World Bank and Asia Development Bank while focused on markets in India, Philippines, China, Peru, Colombia, Ecuador, Azerbaijan and Uzbekistan. He lead CrossKeys and Clearford's entry into the China market and in 2009 Clearford was awarded by the Canada-China Business Council for their market entry strategy. He was part of the leadership team for the Nasdaq/TSX IPO at CrossKeys Systems Corporation. He served as a Director of Asia Pacific Operations, Director of Business Relations and Director of Finance and Administration of CrossKeys. He serves as the Chairman of Canopy Growth Corporation (formerly Tweed Marijuana Inc) and Co-Chairman of Martello Technologies Group Inc. since August 15, 2018 and serves as its Director since April 29, 2013. He serves as a Director of and Bedrocan Cannabis Corp. He has been a Non-Executive Director of TW Holdings Limited since June 1, 2016. He serves as a Director of Carleton University and is Treasurer and Director at the non-profit youth organization Canadian World Youth. He served as a Director of Thermal Energy International Inc. since October 25, 2012 until November 28, 2016. He served as a Director of Clearford Industries Inc. from August 22, 2006 to October 16, 2013. He served as Director of Marchwell Ventures Ltd. from September 12, 2000 to November 17, 2011. He served as Director of Brooklin Concrete Products Limited. He was an industry liaison for Newbridge in 1992. He sits as Canada's representative on the World Bank's Water Sanitation Program Advisory Council as well as sitting on the Cleantech Advisory Board for Foreign Affairs Canada. He was Chairman of the Ottawa Community Loan Foundation, Board of Governor for Carleton University. He served as the President of the Nepean Skating Club and past-President of the Carleton University Students Association. He holds Bachelors of Public Administration from Carleton University (1986-1992).
Average tenure of the Canopy Growth management team in years:
Average tenure and age of the Canopy Growth board of directors in years:
Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (CA$) | Value (CA$) | |
---|---|---|---|---|---|---|---|---|---|---|
13. Dec 18 | Buy | David Bigioni | Individual | 12. Dec 18 | 12. Dec 18 | 252 | CA$42.82 | CA$10,791 | ||
11. Dec 18 | Buy | David Bigioni | Individual | 10. Dec 18 | 10. Dec 18 | 3,600 | CA$41.99 | CA$151,164 | ||
11. Dec 18 | Sell | Robert Hanson | Individual | 06. Dec 18 | 06. Dec 18 | -5 | CA$29.85 | CA$-149 | ||
03. Oct 18 | Sell | Murray Goldman | Individual | 28. Sep 18 | 28. Sep 18 | -70,000 | CA$64.28 | CA$-4,499,600 | ||
03. Oct 18 | Sell | Mark Anthony Zekulin | Individual | 27. Sep 18 | 27. Sep 18 | -358,334 | CA$64.70 | CA$-23,182,562 | ||
02. Oct 18 | Sell | Murray Goldman | Individual | 28. Sep 18 | 28. Sep 18 | -300,000 | CA$65.74 | CA$-19,532,431 | ||
02. Oct 18 | Sell | HBAM Holdings Inc | Company | 27. Sep 18 | 27. Sep 18 | -307,845 | CA$64.66 | CA$-19,900,788 | ||
02. Oct 18 | Sell | Onbelay Capital Inc. | Company | 27. Sep 18 | 27. Sep 18 | -48,683 | CA$64.07 | CA$-3,119,120 | ||
02. Oct 18 | Sell | John Bell | Individual | 27. Sep 18 | 27. Sep 18 | -36,350 | CA$64.43 | CA$-2,342,030 | ||
29. Sep 18 | Sell | Christopher Schnarr | Individual | 27. Sep 18 | 27. Sep 18 | -107,868 | CA$65.44 | CA$-7,058,882 | ||
04. Jul 18 | Sell | Murray Goldman | Individual | 29. Jun 18 | 29. Jun 18 | -100,000 | CA$38.63 | CA$-3,823,062 |
Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Companies of this size are usually well known to retail investors, too.
Simply Wall St - – Full articleMid-caps stocks, like Canopy Growth Corporation (TSE:WEED) with a market capitalization of CA$8.32b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. … Today we will look at WEED’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Check out our latest analysis for Canopy Growth
Simply Wall St - – Full articleI’ve put together a brief outline of industry analyst expectations for WEED, its year of breakeven and its implied growth rate. … View our latest analysis for Canopy Growth According to the industry analysts covering WEED, breakeven is near. … How fast will WEED have to grow each year in order to reach the breakeven point by 2020?
Simply Wall St - – Full articleSee our latest analysis for Canopy Growth Does WEED generate an acceptable amount of cash through operations? … With this growth in debt, WEED's cash and short-term investments stands at CA$101.80M , ready to deploy into the business. … I suggest you continue to research Canopy Growth to get a more holistic view of the stock by looking at: Future Outlook: What are well-informed industry analysts predicting for WEED’s future growth?
Simply Wall St - – Full articleI find that Canopy Growth’s ratio of 8.2x is trading slightly above its industry peers’ ratio of 6.96x, which means if you buy Canopy Growth today, you’d be paying a relatively reasonable price for it. … And if you believe that Canopy Growth should be trading at this level in the long run, there’s only an insignificant downside when the price falls to its real value. … Given that Canopy Growth’s share is fairly volatile (i.e.
Simply Wall St - – Full articleInvestors seeking to increase their exposure to growth should consider companies such as Canopy Growth and Sangoma Technologies. … TSX:WEED Future Profit Jan 2nd 18 Sangoma Technologies Corporation (TSXV:STC) Sangoma Technologies Corporation develops, manufactures, distributes, and supports voice and data connectivity components for software-based communication applications worldwide. … TSXV:ICC Future Profit Jan 2nd 18 For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.
Simply Wall St - – Full articleIndividual investors like stocks with a high growth potential. … TOS is expected to deliver an extremely high earnings growth over the next couple of years of 56.41%, bolstered by a significant revenue which is expected to more than double. … TSX:TOS Future Profit Nov 22nd 17 For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.
Simply Wall St - – Full articleCheck out our latest analysis for Canopy Growth Is WEED’s level of debt at an acceptable level? … To assess this, I compare WEED's cash and other liquid assets against its upcoming debt. … Our analysis shows that WEED does have enough liquid assets on hand to meet its upcoming liabilities, which lowers our concerns should adverse events arise.
Simply Wall St - – Full article
Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Name: | Canopy Growth Corporation |
WEED | |
Exchange: | TSX |
Founded: | |
CA$20,379,253,497 | |
343,027,327 | |
Website: | http://www.canopygrowth.com |
Address: |
Canopy Growth Corporation 1 Hershey Drive, Smiths Falls, Ontario, K7A 0A8, Canada |
Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
---|---|---|---|---|---|---|---|
TSX | WEED | Common Shares | The Toronto Stock Exchange | CA | CAD | 27. Mar 2014 | |
NYSE | CGC | Common Shares | New York Stock Exchange | US | USD | 27. Mar 2014 | |
DB | 11L1 | Common Shares | Deutsche Boerse AG | DE | EUR | 27. Mar 2014 | |
LSE | 0UO9 | Common Shares | London Stock Exchange | GB | CAD | 27. Mar 2014 |
Pharmaceuticals | |
Pharmaceuticals & Biotech |
Area | Date (UTC time) |
---|---|
Company Analysis updated: | 2019/02/22 00:35 |
End of day share price update: | 2019/02/21 00:00 |
Last estimates confirmation: | 2019/02/21 |
Last earnings filing: | 2019/02/14 |
Last earnings reported: | 2018/12/31 |
Last annual earnings reported: | 2018/03/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.